Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026)
Lb Pharmaceuticals (LBRX) posted quarterly Cash from Financing Activities of $93.8 million for Q1 2026, up 8119.74% quarter-over-quarter from -$1.2 million in Q4 2025.
Powered by 
Analysis
Lb Pharmaceuticals (LBRX) Cash from Financing Activities (2025 - 2026) Analysis & Trends
Lb Pharmaceuticals' Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $93.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities changed N/A year-over-year to $93.8 million; the TTM figure through Mar 2026 stood at $92.7 million (changed N/A YoY), while the FY2025 annual figure was $302.6 million, up 689.67% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $93.8 million, up from -$1.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $93.8 million in Q1 2026, with the low at -$1.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Lb Pharmaceuticals | 1.49 Bn | 1.49 Bn | - | -19,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | 93.83 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | 303.73 Mn |